NBRVF (Nabriva Therapeutics) Total Equity: $-16.32 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBRVF Nabriva Therapeutics PLC NBRVF
12 GF Score
Price $0.00
View Full Analysis

What is Nabriva Therapeutics Total Equity?

Nabriva Therapeutics NBRVF 12 Total Equity is $-16.32 Mil as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

Nabriva Therapeutics's total equity for the quarter that ended in Jun. 2023 was $-16.32 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nabriva Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics Total Equity Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.63 41.27 33.14 53.35 3.29

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.61 25.62 3.29 -4.36 -16.32
NBRVF
12GF Score
Nabriva Therapeutics PLC NBRVF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nabriva Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nabriva Therapeutics's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=31.765-28.472
=3.29

Nabriva Therapeutics's Total Equity for the quarter that ended in Jun. 2023 is calculated as

Total Equity=Total Assets(Q: Jun. 2023 )-Total Liabilities(Q: Jun. 2023 )
=10.578-26.899
=-16.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-16.32 Mil mean?
Nabriva Therapeutics (NBRVF) has a Total Equity of $-16.32 Mil as of Jun. 2023. The total amount of equity as record on a company's balance sheet. View historical data for Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Total Equity too high?
Nabriva Therapeutics' current Total Equity is $-16.32 Mil. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Total Equity compare to BXRX and INM?
Nabriva Therapeutics' Total Equity of $-16.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current Total Equity is $-16.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Total Equity of $-16.32 Mil. The current Total Equity is $-16.32 Mil. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Total Equity is $-16.32 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score

Get the complete analysis for NBRVF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price